| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/25/1996 | WO1996001847A1 Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown |
| 01/25/1996 | WO1996001637A1 New pharmaceutical preparation for pain management |
| 01/25/1996 | WO1996001561A1 Method of regulating immune function |
| 01/25/1996 | CA2193992A1 New pharmaceutical preparation for pain management |
| 01/24/1996 | EP0693285A2 Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss |
| 01/24/1996 | EP0692975A1 Administration of vaso-active agent and therapeutic agent |
| 01/24/1996 | EP0692969A1 Method of treatment of diseases by deletion of t cells |
| 01/24/1996 | EP0692962A1 Use of steroid antagonists for the therapy and prophylaxis of demential illnesses |
| 01/23/1996 | US5486520 1,3-oxathiolanes useful in the treatment of hepatitis |
| 01/23/1996 | US5485827 Providing nitrogen oxide for breathing |
| 01/23/1996 | CA2154414A1 Combination treatment for inhibiting bone loss |
| 01/20/1996 | CA2154201A1 Use of magnesium hydroxide as a stool softener |
| 01/18/1996 | WO1996001430A2 Screening for nuc inhibitors |
| 01/18/1996 | WO1996001253A2 Pla2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| 01/18/1996 | WO1996001127A1 Camptothecin drug combinations and medicaments with reduced side effects |
| 01/18/1996 | WO1996001122A1 Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain |
| 01/18/1996 | WO1996001121A1 Cancer therapy using lymphotoxin |
| 01/18/1996 | WO1996001115A1 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| 01/18/1996 | WO1996001106A1 Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses |
| 01/18/1996 | DE4426659A1 Control of deficiency diseases by cumulatively building up levels of minerals |
| 01/18/1996 | DE4425255A1 Formulierung zur inhalativen Applikation Formulation for inhalation |
| 01/18/1996 | CA2194277A1 Canptothecin drug combinations and medicaments with reduced side effects |
| 01/18/1996 | CA2194239A1 Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain |
| 01/18/1996 | CA2193685A1 Screening for nuc inhibitors |
| 01/18/1996 | CA2191775A1 Pla2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| 01/18/1996 | CA2191696A1 Cancer therapy using lymphotoxin |
| 01/17/1996 | EP0691972A1 FURO 3,2-b]PYRIDINES AND THIENO 3,2-b]PYRIDINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS |
| 01/17/1996 | EP0691854A1 Conjugates of proteins and bifunctional ligands |
| 01/17/1996 | EP0691852A1 Prodrugs with enhanced penetration into cells |
| 01/17/1996 | EP0691847A1 Use of cyclooxygenase inhibitors for the manufacture of a medicament for enhancing uterine blood perfusion |
| 01/17/1996 | EP0691844A1 Method for treating amyloidosis |
| 01/17/1996 | EP0691814A1 Method and composition for treatment of osteoporosis |
| 01/16/1996 | US5484891 Pure polypeptide able to hybridize under low stringency conditions; glycoproteins |
| 01/16/1996 | US5484833 Derivatives of non-steroidal anti-inflammatory, analgesic and/or antipyretic substances, their use and pharmaceutical formulations containing them |
| 01/16/1996 | US5484816 Stabilized vitamin a composition |
| 01/16/1996 | US5484801 Pharmaceutical composition for inhibiting HIV protease |
| 01/16/1996 | US5484800 Lipid-based liquid medicinal composition |
| 01/16/1996 | US5484724 DNA encoding GLSI |
| 01/16/1996 | US5484612 Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| 01/16/1996 | CA1337930C Method of treating skin injuries using thromboxane a__ receptor antagonists |
| 01/11/1996 | WO1996000584A1 Anti-inflammatory wound healing compositions and methods for preparing and using same |
| 01/11/1996 | WO1996000572A1 Antikeratolytic-wound healing compositions and methods for preparing and using same |
| 01/11/1996 | CA2191605A1 Antikeratolytic-wound healing compositions and methods for preparing and using same |
| 01/11/1996 | CA2191604A1 Anti-inflammatory wound healing compositions and methods for preparing and using same |
| 01/10/1996 | EP0691130A1 Use of rapamycin in the manufacture of a medicament for preventing and heating hyperproliferactive vascular diseases, eventually in combination with mycophenolic acid |
| 01/10/1996 | EP0690871A1 Growth differentiation factor-5 |
| 01/10/1996 | EP0690841A1 Synthetic matrix metalloprotease inhibitors and uses thereof |
| 01/10/1996 | EP0690722A1 Composition and method for reducing toxicity of biologically-active factors |
| 01/10/1996 | EP0471084B1 Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic |
| 01/10/1996 | CN1114650A MDR reversal agents |
| 01/10/1996 | CN1114558A Depigmenting composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof |
| 01/09/1996 | US5482716 Medicaments |
| 01/09/1996 | CA2074639C Pharmaceutical composition suitable for influencing the reticuloendothelic system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying diseases of tumorous origin, a process for preparing same and its use |
| 01/04/1996 | WO1996000396A1 Improved methods for the determination and adjustment of prolactin daily rhythms |
| 01/04/1996 | WO1996000226A1 Substituted azaindolylidene compounds and process for their preparation |
| 01/04/1996 | WO1996000086A1 Therapeutic method and remedy for diabetes |
| 01/04/1996 | WO1996000073A1 Treatment of optic neuritis |
| 01/04/1996 | WO1996000065A1 Tacrine pharmaceutical compositions |
| 01/04/1996 | WO1996000062A1 Dopamine d1 agonists for the treatment of dementia |
| 01/04/1996 | WO1996000058A1 Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| 01/04/1996 | WO1995033464A3 Retroviral protease inhibitor combinations |
| 01/04/1996 | WO1995031985A3 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies |
| 01/04/1996 | CA2193799A1 Dopamine d1 agonists for the treatment of dementia |
| 01/04/1996 | CA2192855A1 Improved methods for the determination and adjustment of prolactin daily rhythms |
| 01/04/1996 | CA2187332A1 Tacrine pharmaceutical compositions |
| 01/03/1996 | EP0689593A1 Inhibition of selected tumor growth with recombinant viral sector |
| 01/03/1996 | EP0689452A1 Composition for oral administration of peptides |
| 01/03/1996 | EP0689450A1 Potassium channel blocking compounds and their use |
| 01/03/1996 | EP0689434A1 Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof |
| 01/03/1996 | EP0689431A1 New use of anti-acne agents |
| 01/03/1996 | EP0275300B1 Recombinant vaccine |
| 01/02/1996 | US5480651 Composition and method for treating nicotine craving in smoking cessation |
| 01/02/1996 | CA2032904C Blocking agents of edrf effect or formation for the treatment of shock |
| 12/29/1995 | CA2152321A1 Compositions for treatment of diabetic complications |
| 12/28/1995 | WO1995035308A1 INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| 12/28/1995 | WO1995035112A2 Modulators of pneumococcal adhesion to cellular targets involving the platelet activating factor receptor, and uses thereof |
| 12/28/1995 | WO1995035110A1 Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders |
| 12/28/1995 | WO1995035099A1 Vitamin/nutrient dosage regimentation |
| 12/28/1995 | CA2193530A1 Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders |
| 12/28/1995 | CA2193362A1 Modulators of pneumococcal adhesion to cellular targets involving the platelet activating factor receptor, and uses thereof |
| 12/27/1995 | EP0688219A1 Reduction of boar odor in meat |
| 12/27/1995 | EP0688213A1 Treatment of tumors with compounds having rxr retinoid receptor agonist activity |
| 12/27/1995 | EP0688209A1 Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
| 12/26/1995 | US5478857 Use of PLA2 inhibitors as treatment for alzheimer's disease |
| 12/26/1995 | US5478848 Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine |
| 12/26/1995 | US5478725 Contacting endometrium sample with monoclonal antibody specific for integrin, assaying, correlating absence with endometriosis |
| 12/26/1995 | US5478577 Administering controlled release dosage form of opiate analgesics |
| 12/26/1995 | US5478558 Administering composition free of serum amyloid P, thrombin activity, infectious agents, antibodies |
| 12/26/1995 | CA2028746C Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| 12/22/1995 | WO1994028924A1 Combination of angiotensin converting enzyme inhibitors and aii antagonists |
| 12/22/1995 | CA2165410A1 Combination of angiotensin converting enzyme inhibitors and all antagonists |
| 12/21/1995 | WO1995034661A1 Fas associated proteins |
| 12/21/1995 | WO1995034571A2 Drug salts |
| 12/21/1995 | WO1995034321A1 Immune modulation with class ii alpha-chain fragments |
| 12/21/1995 | WO1995034319A1 Compositions and methods for the treatment of tumors |
| 12/21/1995 | WO1995034306A1 Use of immunosuppressive agents for the treatment of schizophrenia |
| 12/21/1995 | WO1995030423A3 Cancer treatment and metastasis prevention |
| 12/21/1995 | CA2192844A1 Fas associated proteins |
| 12/21/1995 | CA2191065A1 Compositions and methods for the treatment of tumors |
| 12/21/1995 | CA2169762A1 Immune modulation with class ii alpha-chain fragments |